Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;120(12):e20230167.
doi: 10.36660/abc.20230167.

New Cardiovascular Biomarkers in Breast Cancer Patients Undergoing Doxorubicin-Based Chemotherapy

[Article in Portuguese, English]
Rodrigo Mendonça Cardoso Pestana  1 , Júnea Paolucci Paiva Silvino  1 , Angélica Navarro de Oliveira  2 , Cintia Esteves Soares  3 , Adriano de Paula Sabino  4 , Ricardo Simões  2   3   4 , Karina Braga Gomes  1   4
Affiliations

New Cardiovascular Biomarkers in Breast Cancer Patients Undergoing Doxorubicin-Based Chemotherapy

[Article in Portuguese, English]
Rodrigo Mendonça Cardoso Pestana et al. Arq Bras Cardiol. 2023 Dec.

Abstract
in English, Portuguese

Background: Central Illustration : New Cardiovascular Biomarkers in Breast Cancer Patients Undergoing Doxorubicin-Based Chemotherapy. Cardiovascular diseases (CVDs) are relevant to the management of breast cancer treatment since a substantial number of patients develop these complications after chemotherapy.

Objective: This study aims to evaluate new cardiovascular biomarkers, namely CXCL-16 (C-X-C motif ligand 16), FABP3 (fatty acid binding protein 3), FABP4 (fatty acid binding protein 4), LIGHT (tumor necrosis factor superfamily member 14/TNFS14), GDF-15 (Growth/differentiation factor 15), sCD4 (soluble form of CD14), and ucMGP (uncarboxylated Matrix Gla-Protein) in breast cancer patients treated with doxorubicin (DOXO).

Methods: This case-control study was conducted in an oncology clinic that included 34 women diagnosed with breast cancer and chemotherapy with DOXO and 34 control women without cancer and CVD. The markers were determined immediately after the last cycle of chemotherapy. The statistical significance level adopted was 5%.

Results: The breast cancer group presented higher levels of GDF-15 (p<0.001), while control subjects had higher levels of FABP3 (p=0.038), FABP4 (p=0003), sCD14, and ucMGP (p<0.001 for both). Positive correlations were observed between FABPs and BMI in the cancer group.

Conclusion: GDF15 is an emerging biomarker with potential clinical applicability in this scenario. FABPs are proteins related to adiposity, which are potentially involved in breast cancer biology. sCD14 and ucMGP engage in inflammatory and vascular calcification. The evaluation of these novel cardiovascular biomarkers could be useful in the management of breast cancer chemotherapy with DOXO.

Fundamento: Figura Central: Novos Biomarcadores Cardiovasculares em Pacientes com Câncer de Mama Submetidas a Quimioterapia à Base de Doxorrubicina. As doenças cardiovasculares (DCV) são relevantes para o manejo do tratamento do câncer de mama, uma vez que um número significativo de pacientes desenvolve essas complicações após a quimioterapia.

Objetivo: Este estudo teve como objetivo avaliar novos biomarcadores cardiovasculares, sendo eles CXCL-16 (ligante de motivo C-X-C 16), FABP3 (proteína de ligação a ácidos graxos 3), FABP4 (proteína de ligação a ácidos graxos 4), LIGHT (membro da superfamília do fator de necrose tumoral 14/TNFS14), GDF-15 (fator de crescimento/diferenciação 15) , sCD4 (forma solúvel de CD14) e ucMGP (matriz Gla-proteína não carboxilada) em pacientes com câncer de mama tratadas com doxorrubicina (DOXO).

Métodos: Este estudo de caso-controle foi realizado em uma clínica oncológica, incluindo 34 mulheres com diagnóstico de câncer de mama tratadas com quimioterapia com DOXO e 34 mulheres controle, sem câncer ou DCV. Os marcadores foram determinados imediatamente após o último ciclo de quimioterapia. O nível de significância estatística adotado foi de 5%.

Resultados: O grupo com câncer de mama apresentou níveis mais elevados de GDF-15 (p<0,001), enquanto os indivíduos controle apresentaram níveis mais elevados de FABP3 (p=0,038), FABP4 (p=0003), sCD14 e ucMGP (p<0,001 para ambos). Correlações positivas foram observadas entre FABPs e IMC no grupo com câncer.

Conclusão: GDF15 é um biomarcador emergente com potencial aplicabilidade clínica neste cenário. FABPs são proteínas relacionadas à adiposidade, potencialmente envolvidas na biologia do câncer de mama. sCD14 e ucMGP estão envolvidos na calcificação inflamatória e vascular. Acima de tudo, a avaliação destes novos biomarcadores cardiovasculares pode ser útil no tratamento da quimioterapia do câncer de mama com DOXO.

PubMed Disclaimer

Conflict of interest statement

Potencial conflito de interesse

Não há conflito com o presente artigo

Figures

Figura Central
Figura Central. : Novos Biomarcadores Cardiovasculares em Pacientes com Câncer de Mama Submetidas a Quimioterapia à Base de Doxorrubicina
Figura 1
Figura 1. – Marcadores cardiovasculares comparando pacientes com câncer de mama e grupo controle. CXCL-16: Ligante do motivo C-X-C 16; FABP3: proteína de ligação a ácidos graxos 3; FABP4: proteína de ligação a ácidos graxos 4; LIGHT: membro da superfamília do fator de necrose tumoral 14/TNFS14; GDF-15: Fator de crescimento/diferenciação 15; sCD4: forma solúvel de CD14; ucMGP: Proteína Gla de matriz não carboxilada; BC: pacientes com câncer de mama; HS: controles saudáveis * Significativo (p<0,05). ** Significativo (p<0,001).
Figura 2
Figura 2. – Curva de COR para níveis de GDF-15, considerando pacientes com câncer de mama tratados com doxorrubicina x grupo controle.
Central Illustration
Central Illustration. : New Cardiovascular Biomarkers in Breast Cancer Patients Undergoing Doxorubicin-Based Chemotherapy
Figure 1
Figure 1. – Cardiovascular markers comparing breast cancer patients and control subjects. CXCL-16: C-X-C motif ligand 16; FABP3: fatty acid binding protein 3; FABP4: fatty acid binding protein 4; LIGHT: tumor necrosis factor superfamily member 14/TNFS14; GDF-15: Growth/differentiation factor 15; sCD4: soluble form of CD14; ucMGP: uncarboxylated Matrix Gla-Protein; BC: breast cancer patients; HS: healthy control subjects * Significant (p<0.05). ** Significant (p<0.001).
Figure 2
Figure 2. – ROC curve for GDF-15 levels considering the breast cancer patients treated with doxorubicin x control group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mansur AP, Favarato D. Cardiovascular and Cancer Death Rates in the Brazilian Population Aged 35 to 74 Years, 1996-2017. Arq Bras Cardiol. 2021;117(2):329–340. doi: 10.36660/abc.20200233. - DOI - PMC - PubMed
    1. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement from the American Heart Association. Circulation. 2018;137(8):e30–e66. doi: 10.1161/CIR.0000000000000556. - DOI - PMC - PubMed
    1. Maki Y, Sueta D, Ishii M, Yamanouchi Y, Fujisue K, Yamanaga K, et al. Associations of Cardiovascular Risk Factors with Survival Outcomes in a Cancer Registration: Findings from the KUMAMON Registry. Medicine. 2021;100(47):e27921. doi: 10.1097/MD.0000000000027921. - DOI - PMC - PubMed
    1. Leiva O, AbdelHameid D, Connors JM, Cannon CP, Bhatt DL. Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021;3(5):619–634. doi: 10.1016/j.jaccao.2021.08.011. - DOI - PMC - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between Different Polychemotherapy Regimens for Early Breast Cancer: Meta-Analyses of Long-Term Outcome Among 100,000 Women in 123 Randomised Trials. Lancet. 2012;379(9814):432–444. doi: 10.1016/S0140-6736(11)61625-5. - DOI - PMC - PubMed